-
Graves病甲状腺功能亢进症(甲亢) 是一种常见的自身免疫性甲状腺疾病,约占全部甲亢的85%,其表现为体内高水平甲状腺激素所致的各种临床症状和体征。由于Graves病甲亢是一种高代谢疾病,可使体内血糖代谢旺盛,而糖代谢存在多条途径,如糖异生及糖原分解等均受到甲状腺激素的影响,因此二者间具有密切的联系。临床工作中发现,Graves病甲亢患者常伴有血糖水平升高,可出现继发性糖尿病或合并糖尿病。文献报道,7 %~75%的甲亢患者伴糖耐量异常或糖尿病,而大多数是由Graves病甲亢引起[1]。以下就Graves病甲亢与血糖代谢之间的关系、血糖升高的发生机制及其131I治疗的预后作一综述。
Graves病甲状腺功能亢进症与血糖代谢
Graves disease hyperthyroidism and glycometabolism
-
摘要: Graves病甲状腺功能亢进症(甲亢)患者常伴有糖代谢紊乱,其机制主要与胰岛β细胞功能受损及胰岛素抵抗有关,而免疫遗传因素也起一定的作用。在131I和抗甲状腺药物治疗后,伴随着甲状腺激素水平的恢复,血糖逐渐开始下调并恢复正常。因此,对Graves病甲亢伴糖代谢紊乱患者进行积极的早期治疗有助于血糖的控制及并发症的预防。Abstract: The patients with Graves disease hyperthyroidism are often accompanied by disorder of glycometabolism.β-cell dysfunction and insulin resistance play a main role in this disease, while the immune and genetic factors are also relevant with the disease. The blood glycose level can become normal gradually with the recovery of thyroid hormone after 131I and antithyroid drug treatment. Therefore, the blood glycose level could be improved and complications could be prevented by early treatment in the patients with Graves disease hyperthyroidism accompanied with glycometabolism disorder is helpful for improving the blood glycose level.
-
Key words:
- Gravesdisease /
- Hyperthyroidism /
- Glucosemetabolism /
- Iodineradioisotopes /
- Brachytherapy
-
[1] 齐今吾. 内分泌疾病相关高血糖和(或)糖尿病// 刘新民, 齐今吾, 杨晓凤, 等. 内分泌疾病: 鉴别诊断与治疗学. 北京: 人民军医出版社, 2009: 358.
[2] Bhattacharyya A, Wiles PG. Diabetic ketocidosis precipitated by thyrotoxicosis. Postgrad Med J, 1999, 75(833): 291-292. [3] Moller N, Nielsen S, Nyholm B, et al. Glucose turnover, fuel oxida-tion and forearm substrate exchange in patients with thyrotoxicosis before and after medical treatment. Clin Endocrinol (Oxf), 1996, 44(4): 453-459. doi: 10.1046/j.1365-2265.1996.692514.x [4] Loeb JN. Metabolic changes in thyrotoxicosis//Braverman LE, Utiger RD. Werner and Ingbar's the thyroid. Philadelphi a: Lippincott-Raven, 1996: 687-693. [5] Gasińska T, Nowak S, Beldzik A, et al. Levels of free fatty acids in plasma, tissue utilization coefficient of glucose K and insulin secre-tion following intravenous glucose load in hyper-thyroid patients treated with propranolol or acebutolol. Pol Tyg Lek, 1994, 49 (1-3): 7-10. [6] Mokuno T, Uchimura K, Hayashi R, et al. Glucose transporter 2 concentrations in hyper-and hypothyroid rat livers. J Endocrinol, 1999, 160(2): 285-289. doi: 10.1677/joe.0.1600285 [7] Bech K, Damsbo P, Eldrup E, et al. Beta-cell function and glucose and lipidoxidation in Graves′ disease. Clin Endocrinol(oxf), 1996, 44(1): 59-66. doi: 10.1046/j.1365-2265.1996.636458.x [8] Yki-Järvinen H. Toxicity of hyperglycaemia in type 2 diabetes. Diabetes Metab Rev, 1998, 14 (Suppl 1): S45-S50. [9] Stumvoll M, Fritsche A, Stefan N, et al. Evidence against a ratelimiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction. J Clin Endocrinol Metab, 2001, 86(3): 1235-1239. [10] Røder ME, Schwartz RS, Prigeon RL, et al. Reduced pancreatic B cell compensation to the insulin resistance of aging: impact on proinsulin and insulin levels. J Clin Endocrinol Metab, 2000, 85(6): 2275-2280. [11] Larsson H, Ahrén B. Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. J Clin Endocrinol Metab, 1999, 84(6): 2068-2074. [12] Eizirik DL, Darville MI. Beta-cell apoptosis and defense mecha-nisms: lessons from type 1 diabetes. Diabetes, 2001, 50(Suppl 1): S64-S69. [13] Jörns A, Tiedge M, Lenzen S. Thyroxine induces pancreatic beta cell apoptosis in rats. Diabetologia, 2002, 45(6): 851-855. doi: 10.1007/s00125-002-0842-5 [14] Yavuz DG, Yüksel M, Deyneli O, et al. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goiter patients. Clin Endocrinol, 2004, 61(4): 515-521. doi: 10.1111/j.1365-2265.2004.02123.x [15] Riis AL, Gravholt CH, Djurhuns CB, et al. Elevated regional lipolysis in hyperthyroidism. J Clin Endocrinol Matab, 2002, 87(10): 4747-4753. doi: 10.1210/jc.2002-020174 [16] Dimitriadis G, Mitrou P, Lambadiari V, et al. Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism. J Clin Endocrin Metab, 2006, 91(3): 1112-1118. doi: 10.1210/jc.2005-0960 [17] Shimabukuro M, Zhou YT, Levi M, et al. Fatty acid induced beta-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA, 1998, 95(5): 2498-2502. doi: 10.1073/pnas.95.5.2498 [18] Heimberg H, Heremans Y, Jobin C, et al. Inhibition of cytokine induced NF-kappa B activation by adenovirus mediated expression of a NF-kappaB super-repressor prevent beta-cell apoptosis. Diabetes, 2001, 50(10): 2219-2224. doi: 10.2337/diabetes.50.10.2219 [19] Iossa S, Lionetti L, Mollica MP, et al. Fat balance and serum leptin concentrations in normal, hypothyroid, and hyperthyroid rats. Int J Obes Relat Metab Disord, 2001, 25(3): 417-425. doi: 10.1038/sj.ijo.0801516 [20] Roubsanthisuk W, Watanakejorn P, Tunlakit M, et al. Hyperthy-roidism induces glucose intolerance by lowering both insulin secretion and peripheral insulin sensitivity. J Med Assoc Thai, 2006, 89(Suppl 5): S133-S140. [21] Jenkins RC, Valcavi R, Zini M, et al. Association of elevated insulin-like growth factor binding protein-1 with insulin resistance in hyperthyroidism. Clin Endocrinol (Oxf), 2000, 52(2): 187-195. doi: 10.1046/j.1365-2265.2000.00924.x [22] Fukuchi M, Shimabukuro M, Shimajiri Y, et al. Evidence for a deficient pancreatic beta-cell response in a rat model of hyperthy-roidism. Life Sci, 2002, 71(9): 1059-1070. doi: 10.1016/S0024-3205(02)01791-5 [23] Douglas RS, Gianoukakis AG, Kamat S, et al. Aberrant expression of the insulin-like crowth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol, 2007, 178(5): 3281-3287. doi: 10.4049/jimmunol.178.5.3281 [24] Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves'disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol, 2008, 181(8): 5768-5774. doi: 10.4049/jimmunol.181.8.5768 [25] Maugendre D, Sonnet E, Derrien C, et al. Combined analysis of long-term anti-beta-cell humoral reactivity in type 1 diabetes with and without thyroid disease. Diabetes Metab, 1999, 25(1): 28-33. [26] Wu TJ, Huang SM, Taylor RL, et al. Abnormal proinsulin levels in thyroid dysfunction measured by a sensitive proinsulin immuno-chemiluminoassay. Ann Clin Lab Sci, 1998, 28(2): 82-87. [27] Hwang IK, Kim IY, Kim YN, et al. Effects of methimazole on the onset of type 2 diabetes in leptin receptor-deficient rats. J Vet Med Sci, 2009, 71(3): 275-280. doi: 10.1292/jvms.71.275 [28] 闫瑞红, 杨天正, 周振虎, 等. 131I治疗Graves病合并糖尿病的疗效分析. 中华核医学杂志, 2008, 28(5): 351.
[29] 赵德善, 孔繁振, 司宏伟, 等. 儿童和青少年甲状腺功能亢进症的131I治疗. 中华内分泌代谢杂志, 2006, 22(6): 566-568. doi: 10.3760/j.issn:1000-6699.2006.06.017
[30] 廖二元, 超楚生. 内分泌学// 戴如春, 廖二元. 继发性糖尿病与遗传性糖尿病. 北京: 人民卫生出版社, 2003: 1620.
计量
- 文章访问数: 1203
- HTML全文浏览量: 725
- PDF下载量: 2